The George Mason RBL has expertise in studying defensins. I am confident they will continue the Brilacidin studies as an antiviral against a variety of viruses. Many of these viruses have no significant treatments and are problems in the US and many parts of the world. The RBL should be able to continue to obtain funding since the in vitro studies are relatively inexpensive.
I have been told inhalers require extensive FDA testing.
I am sure IPIX would be open to more centers studying Brilacidin for viruses; it is just a matter of funding. Some of the centers will want the company to pay for the studies or they will want a percentage of earnings. Leo has not shown any interest in those deals.
The Covid studies are going to dominate all medical studies for at least a few years.
News 
Market Data 
Discover 
